Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Rain Oncology's share price for the quarter that ended in Sep. 2023 was $0.8618. Rain Oncology's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 36.38 Mil. Therefore, Rain Oncology's market cap for the quarter that ended in Sep. 2023 was $31.35 Mil.
Rain Oncology's quarterly market cap
declined
from Mar. 2023 ($317.81 Mil) to Jun. 2023 ($43.65 Mil) and
declined
from Jun. 2023 ($43.65 Mil) to Sep. 2023 ($31.35 Mil).
Rain Oncology's annual market cap
increased
from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($341.01 Mil) but then
declined
from Dec. 2021 ($341.01 Mil) to Dec. 2022 ($290.32 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rain Oncology's Enterprise Value for Today is $-32.85 Mil.
Rain Oncology Market Cap Historical Data
The historical data trend for Rain Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rain Oncology's Market Cap
For the Biotechnology subindustry, Rain Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rain Oncology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rain Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Rain Oncology's Market Cap falls into.
Rain Oncology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rain Oncology's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rain Oncology (NAS:RAIN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rain Oncology Market Cap Related Terms
Thank you for viewing the detailed overview of Rain Oncology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Rain Oncology (Rain Oncology) Business Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAIN has been successfully added to your 